Dr. Alejandro Martín-Moltalvo
We live in an era in which life expectancy has reached unprecedented levels. But what is the point of living longer if we cannot guarantee that those years will be filled with health, independence and well-being?
In our laboratory, led by Dr Alejandro Martín-Montalvo at CABIMER, we work passionately to answer this essential question: how can we age better?
Our research is at the forefront of biomedicine. We study how to delay the deterioration associated with ageing and prevent chronic diseases associated with age. With more than 60 scientific publications, four patents, and the support of multiple funding agencies, our team has demonstrated that it is possible to improve health and even prolong life in animal models using compounds such as metformin, sirtuin activators, or strategies to enhance cysteine persulfation.
These findings are not only promising: they are the seed of new therapeutic strategies for our population.
Our approach is deeply integrative. We work with everything from simple models such as yeast to mice and human patients, collaborating closely with leading research groups in Europe and the United States.
But we don’t just do science: we also train the next generation of researchers, with a firm commitment to excellence and social impact. This dedication has been recognised with awards such as the CSIC Scientific Excellence Award and various national awards in the areas of diabetes, nutrition and health.
Our current projects are guided by a clear purpose: not only to add years to life, but life to years. We want older people to live longer, yes, but above all, we want them to live life to the fullest.
To achieve this, we need your support. Every donation—no matter how small—makes a difference: it speeds up our trials, allows us to acquire advanced technology, and contributes to the training of scientists dedicated to transforming society.
Investing in our research means investing in science that touches lives, offers hope, and builds a more dignified tomorrow for everyone.
